TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer

Oncology Reports

Volumn 15, Issue 4, 2006, Pages 949-956

  Rogounovitch, Tatiana I ^a   Saenko, Vladimir A ^a,b   Ashizawa, Kiyoto ^c   Sedliarou, Ilya A ^a   Namba, Hiroyuki ^a   Abrosimov, Aleksandr Yu ^a,b   Lushnikov, Eugeny F ^b   Roumiantsev, Pavel O ^b   Konova, Marina V ^b   Petoukhova, Natalia S ^b   Tchebotareva, Irina V ^b   Ivanov, Viktor K ^b   Chekin, Sergei Yu ^b   Bogdanova, Tatiana I ^d   Tronko, Mykola D ^d   Tsyb, Anatoly F ^b   Thomas, Gerry A ^e   Yamashita, Shunichi ^a,f  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^d STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^e SINGLETON HOSPITAL   (United Kingdom)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cancer risk; Chernobyl; Papillary thyroid cancer; Radiation; TP53 polymorphism

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER STAGING; CHILD; CODON; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; INFANT; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MISSENSE MUTATION; NEWBORN; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PATHOLOGY; PRESCHOOL CHILD; RADIATION EXPOSURE; RADIATION INJURY; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; ALLELES; BASE SEQUENCE; CARCINOMA, PAPILLARY; CHILD; CHILD, PRESCHOOL; CODON; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM STAGING; NEOPLASMS, RADIATION-INDUCED; POLYMORPHISM, GENETIC; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746401185     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.4.949     Document Type: Article

References (48)

1. Slee EA, O'Connor DJ and Lu X: To die or not to die: how does p53 decide? Oncogene 23: 2809-2818, 2004. (Pubitemid 38638844)
2. Vogelstein B, Lane D and Lvine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
3. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002. (Pubitemid 37328926)
4. Sansome C, Zaika A, Marchenko ND and Moll UM: Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett 488: 110-115, 2001. (Pubitemid 32103581)
5. Marchenko ND, Zaika A and Moll UM: Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275: 16202-16212, 2000. (Pubitemid 30366932)
6. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003. (Pubitemid 36278852)
7. Zilfou JT, Hoffman WH, Sank M, George DL and Murphy M: The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol 21: 3974-3985, 2001. (Pubitemid 32476459)
8. Buyru N, Tigli H and Dalay N: P53 codon 72 polymorphism in breast cancer. Oncol Rep 10: 711-714, 2003.
9. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA and Borresen-Dale AL: The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11: 1684-1688, 2002.
10. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G and Banks L: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229-234, 1998. (Pubitemid 28261713)
11. Arbel-Alon S, Menczer J, Feldman N, Glezerman M, Yeremin L and Friedman E: Codon 72 polymorphism of p53 in Israel jewish cervical cancer patients and healthy women. Int J Gynecol Cancer 12: 741-744, 2002. (Pubitemid 35388043)
12. Papadakis ED, Soulitzis N and Spandidos DA: Assocation of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87: 1013-1018, 2002. (Pubitemid 35305655)
13. Cairey-Remonnay S, Humbey O, Mougin C, Algros MP, Mauny F, Kanitakis J, Euvrard S, Laurent R and Aubin F: TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. J Invest Dermatology 118: 1026-1031, 2002. (Pubitemid 34639182)
14. Boltze C, Roessner A, Landt O, Szibor R, Peters B and Schneider-Stock R: Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 21: 1151-1154, 2002.
15. Granja F, Morari J, Morari EC, Correa LAC, Assumpcao LVM and Ward LS: Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 210: 151-157, 2004. (Pubitemid 38748685)
16. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ and De Pancorbo MM: Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 193: 199-205, 2003. (Pubitemid 36428903)
17. Hogdall EV, Hogdall CK, Christensen L, Glud E, Blaakaer J, Bock JE, Vuust J, Norgaard-Pedersen B and Kjaer SK: Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 22: 1859-1864, 2002. (Pubitemid 34839209)
18. Biros E, Kalina I, Kohut A, Bogyiova E, Salagovic J and Sulla I: Allelic and haplotype frequencies of the p53 polymorphisms in brain tumor patients. Physiol Res 51: 59-64, 2002. (Pubitemid 34266443)
19. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA and Jacobs IJ: p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352: 871-872, 1998. (Pubitemid 28416721)
20. Klaes R, Ridder R, Schaefer U, Benner A and von Knebel Doeberitz M: No evidence of p53 allele-specific predisposition in human papillomavirus- associated cervical cancer. J Mol Med 77: 299-302, 1999. (Pubitemid 29146581)
21. Tachezy R, Mikyskova I, Salakova M and van Ranst M: Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism. Hum Genet 105: 564-566, 1999. (Pubitemid 30026033)
22. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y and Tajima K: No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 181: 81-85, 2002. (Pubitemid 34326437)
23. Rubino C, Cailleux AF, De Vathaire F and Schlumberger M: Thyroid cancer after radiation exposure. Eur J Cancer 38: 645-647, 2002. (Pubitemid 34251386)
24. Mettler FH Jr, Becker DV, Wachholz BW and Bouville AC: Chernobyl: 10 years later. J Nucl Med 37: 24N, 26N-27N, 1996.
25. Jacob P, Kenigsberg Y, Zvonova I, Goulko G, Buglova E, Heidenreich WF, Golovneva A, Bratilova AA, Drozdovitch V and Paretzke HG: Childhood exposure due to the Chernobyl accident and thyroid cancer risk in contaminated areas of Belarus and Russia. Br J Cancer 80: 1461-1469, 1999. (Pubitemid 29308619)
26. Hillebrandt S, Streffer C, Reiners C and Demidchik E: Mutations in p53 tumor suppressor gene in thyroid carcinomas of children from areas contaminated by the Chernobyl accident. Int J Radiat Biol 69: 39-45, 1996. (Pubitemid 26078360)
27. Nikiforov YE, Nikiforova MN, Gnepp DR and Fagin JA: Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene 13: 687-693, 1996. (Pubitemid 26312895)
28. Suchy B, Waldmann V, Klugbauer S and Rabes HM: Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br J Cancer 77: 952-955, 1998. (Pubitemid 28101785)
29. Salvatore D, Celetti A, Fabien N, Paulin C, Martelli ML, Battaglia C, Califano D, Monaco C, Viglietto G and Fusco A: Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol 134: 177-183, 1996. (Pubitemid 26062419)
30. Yang T, Namba H, Hara T, Takamura N, Nagayama Y, Fukata S, Ishikawa N, Kuma K, Ito K and Yamashita S: p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis in thyroid cells. Oncogene 14: 1511-1519, 1997. (Pubitemid 27182833)
31. Ivanov VK, Gorski AI, Maksioutov MA, Vlasov OK, Godko AM, Tsyb AF, Tirmarche M, Valenty M and Verger P: Thyroid cancer incidence among adolescents and adults in the Bryansk region of Russia following the Chernobyl accident. Health Physics 84: 46-60, 2003. (Pubitemid 35471047)
32. Hedinger C, Williams ED and Sobin LH: Histological typing of thyroid tumors. In: WHO International Histological Classification of Tumors. 2nd edition. Hedinger C, Williams ED and Sobin LH (eds). Springer-Verlag, Berlin, 1988.
33. De Groot LJ, Kaplan EL, McCormick M and Straus FH: Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71: 414-424, 1990.
34. SAS/STAT User's Guide, Version 8. Cary, NC: SAS Insitute Inc., p3884, 1999.
35. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH and Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184, 1993. (Pubitemid 23037270)
36. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N and Akiyama M: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369-1371, 1992.
37. Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, Giardiello FM, Kinzler KW and Vogelstein B: Small changes in expression affect predisposition to tumorigenesis. Nat Genet 30: 25-26, 2002.
38. Nikiforov YE and Gnepp DR: Pathomorphology of thyroid gland lesions associated with radiation exposure: the Chernobyl experience and review of the literature. Adv Anat Pathol 6: 78-91, 1999.
39. Williams D: Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer 2: 543-549, 2002.
40. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Trope CG and Helland A: Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24: 21-34, 2004. (Pubitemid 38859221)
41. Zhang ZW, Laurence NJ, Hollowood A, Newcomb P, Moorghen M, Gupta J, Feakins R, Farthing MJ, Alderson D and Holly J: Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma. Clin Cancer Res 10: 131-135, 2004. (Pubitemid 38114171)
42. Tuttle RM and Becker DV: The Chernobyl accident and its consequences: update at the millennium. Semin Nucl Med 30: 133-140, 2000. (Pubitemid 30211276)
43. Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13: 3-16, 2002.
44. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA and Nikiforov YE: Oncogenic AKAP9- BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115: 94-101, 2005. (Pubitemid 40385509)
45. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI and Nikiforov YE: Low prevalence of BRAF mutations in radiationinduced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209: 1-6, 2004. (Pubitemid 38656111)
46. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M and Sobrinho- Simoes M: BRAF mutations are not a major event in post- Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4267-4271, 2004.
47. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K and Yamashita S: Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4280-4284, 2004. (Pubitemid 39244426)
48. Madeleine MM, Shera K, Schwartz SM, Daling JR, Galloway DA, Wipf GC, Carter JJ, McKnight B and McDougall JK: The p53 Arg72Pro polymorphism, human papillomavirus and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev 9: 225-227, 2000. (Pubitemid 30111949) Technology Technology Technology